Marvell's 2031 target is nearly double what Wall Street had. Memory stocks went the other way

Tuesday's record close in the S&P 500 hid a lot of churn underneath. The day's biggest company-specific stories split the technology trade in two, turned a weekend rumour into a signed deal, and left the life-sciences tools group as the session's clear loser. Here is what moved and why, with closing prices.

Marvell: a target that dwarfed the forecasts

Marvell Technology closed up 5.81% at $287.01 after its investor day in New York. The stock had briefly fallen about 3% as the meeting began, then reversed to trade as much as 10% higher, according to Investing.com.

The reason was the size of the numbers. Marvell set a fiscal 2031 revenue framework of $70 billion to $90 billion, its first guidance for that year. The $80 billion midpoint compares with an analyst consensus of roughly $47 billion, per CNBC and Investing.com, and with the $8.2 billion in revenue Marvell reported for its most recent fiscal year. The company also raised its fiscal 2028 revenue target to $20 billion, against the $18.17 billion analysts polled by FactSet had expected, and set a fiscal 2031 earnings-per-share target of $30 or more.

According to Investing.com, chief executive Matt Murphy framed the plan around a projected $400 billion total addressable market by 2030 for the custom chips and optical-networking components Marvell sells into AI data centers. Peers moved with it: Ciena closed up 13.85% at $443.65, and Benzinga reported gains of about 8% for Astera Labs and 6% for Credo Technology. A five-year framework is a company's own projection, not a forecast anyone has to honor, which is why the stock's reaction was a fraction of the gap between Marvell's range and the consensus.

Memory and storage: the other half of the AI trade

The same session was rough for the companies that store the data. Seagate Technology fell 9.18% to $805.63 and Western Digital dropped 6.93% to $411.04, as investors reassessed the outlook for demand and profits tied to the data-center buildout, CNBC reported. SanDisk and the Roundhill Memory ETF also declined. No single company announcement drove the slide, and both stocks had risen on Monday — Western Digital by about 6% — before giving it back.

Option Care Health: the rumour is now a contract

Option Care Health closed up 32.65% at $31.00 after CD&R and McKesson announced a definitive agreement to acquire the home-infusion provider for $32.05 a share in cash, an enterprise value of about $5.8 billion. Monday's Financial Times report had described talks; Tuesday's announcement, and an 8-K filed with regulators, confirmed the merger agreement was signed on October 5.

The structure matches what was reported. CD&R will hold about 51% and McKesson will invest about $1.4 billion for about 49%, with a framework for McKesson to buy CD&R's interest later, subject to conditions and regulatory approvals. Option Care will remain a separate company under its own management. The stock's close sits about 3.3% below the deal price, the gap investors typically leave for the time and risk involved in getting a transaction closed. McKesson shares rose 0.68% to $921.67.

Lamb Weston: a beat and a higher range

Lamb Weston rose 7.49% to $47.91 after first-quarter results came in ahead of expectations: adjusted earnings of 75 cents a share on $1.67 billion of revenue, against the FactSet consensus of 59 cents and $1.65 billion. The potato-products maker also raised its full-year adjusted earnings range to $3.05 to $3.35 a share, from $2.95 to $3.25. The shares had been up more than 11% at midday.

The losing side: life-sciences tools

Healthcare was the only S&P 500 sector to decline on Tuesday, and the sharpest losses came in genomics and life-sciences tools. Twist Bioscience fell 18.55% to $166.97 and 10x Genomics dropped 17.47% to $80.66. The midday movers coverage we reviewed did not cite a company-specific announcement for either. Moderna fell 7.75% to $187.46, giving back part of a run that CNBC noted had left it more than 130% higher over three months.

What carries into Wednesday

For Marvell and the networking group, the question is whether the long-range framework holds up to analysts rebuilding their models in the days after the event. For storage, it is whether Tuesday was a one-day reassessment or the start of a broader rotation inside the AI trade. Option Care now trades as a deal stock, tied to the $32.05 price and the path to closing. All of them face the same backdrop on Wednesday: the Fed's September minutes and a $39 billion 10-year Treasury auction.